Pharma News

The FDA has accepted Apellis Pharmaceuticals’ major amendment to its new drug application (NDA) for pegcetacoplan for the treatment of patients with geographic atrophy secondary to age-related m...

Nona will offer access to its technologies and antibody generation services to Dragonfly for the targets chosen by the latter.

The FDA has granted Breakthrough Therapy status for Iveric Bio’s Zimura (avacincaptad pegol)  for geographic atrophy secondary to age-related macular degeneration (AMD) which leads to progre...

While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioScie...

ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future. ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatmen...

The U.S. Food and Drug Administration approves the second interchangeable biosimilar insulin product to Lantus (insulin glargine), Eli Lilly’s Rezvoglar (insulin glargine-aglr).   ...

The FDA has approved Provention Bio’s Biologics License Application (BLA) for Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years a...

Camber Pharmaceuticals is pleased to announce the addition of Lamotrigine ER Tablets to its current portfolio.

A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected mor...

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid, Roche’s RoActemra, and Eli Lilly’s Olumiant – but turned down another fiv...

The FDA has issued 29 new product-specific draft guidances and 22 revised draft guidances for complex and non-complex generic drug products.